Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Viking Fund Management LLC

Viking Fund Management LLC boosted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 45.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 318,700 shares of the biopharmaceutical company's stock after buying an additional 100,000 shares during the period. Bristol-Myers Squibb makes up approximately 2.8% of Viking Fund Management LLC's portfolio, making the stock its 4th biggest position. Viking Fund Management LLC's holdings in Bristol-Myers Squibb were worth $19,438,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of BMY. AEGON ASSET MANAGEMENT UK Plc lifted its holdings in Bristol-Myers Squibb by 1.4% during the 1st quarter. AEGON ASSET MANAGEMENT UK Plc now owns 228,404 shares of the biopharmaceutical company's stock worth $13,939,000 after buying an additional 3,139 shares in the last quarter. Bremer Bank National Association purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth $200,000. RFG Advisory LLC raised its stake in shares of Bristol-Myers Squibb by 67.1% in the first quarter. RFG Advisory LLC now owns 27,915 shares of the biopharmaceutical company's stock valued at $1,703,000 after acquiring an additional 11,208 shares in the last quarter. InvesTrust grew its stake in Bristol-Myers Squibb by 0.4% during the 1st quarter. InvesTrust now owns 115,162 shares of the biopharmaceutical company's stock worth $7,024,000 after purchasing an additional 513 shares in the last quarter. Finally, Merit Financial Group LLC increased its holdings in Bristol-Myers Squibb by 21.6% during the 1st quarter. Merit Financial Group LLC now owns 51,601 shares of the biopharmaceutical company's stock worth $3,147,000 after purchasing an additional 9,166 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded down $0.12 on Thursday, reaching $47.84. The company's stock had a trading volume of 12,729,192 shares, compared to its average volume of 13,060,976. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The stock has a market capitalization of $97.35 billion, a P/E ratio of -10.82, a PEG ratio of 2.07 and a beta of 0.39. The stock's 50-day moving average is $49.82 and its two-hundred day moving average is $55.19. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period last year, the company earned ($4.40) earnings per share. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction on Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.09% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on BMY. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Jefferies Financial Group dropped their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Finally, Piper Sandler began coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.